



June 14, 2024

Company name: PeptiDream Inc.
Representative: Patrick C. Reid, President and CEO
(Securities code: 4587; TSE Prime Market)
Inquiries: Yuko Okimoto, Head of Investor Relations
(Tel: +81-44-223-6612)

(Amendment to Original Disclosure) PeptiDream Announces Expansion
of Peptide Discovery Collaboration with Novartis

KANAGAWA, JAPAN – June 14, 2024 - PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream") (Tokyo: 4587) today announced the expiration of the 30-day waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR Act") in connection with 30 April 2024 announced expansion of its peptide discovery collaboration ("the Agreement") with Swiss-based Novartis Pharma AG (NYSE: NVS). As a result, the Agreement became effective on June 13, 2024 and PeptiDream will receive an upfront payment of \$180 million USD (28.25 billion JPY*1) from Novartis.

*1: 1 USD= 156.92JPY

Future outlook

This agreement has been factored in our consolidated financial forecasts for the fiscal year ending December 31, 2024, which was announced on May 14, 2024 and there are no changes to our forecast.